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Genetic screens reveal a central role for heme
metabolism in artemisinin susceptibility
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Artemisinins have revolutionized the treatment of Plasmodium falciparum malaria; however,
resistance threatens to undermine global control efforts. To broadly explore artemisinin
susceptibility in apicomplexan parasites, we employ genome-scale CRISPR screens recently
developed for Toxoplasma gondii to discover sensitizing and desensitizing mutations. Using a
sublethal concentration of dihydroartemisinin (DHA), we uncover the putative transporter
Tmem14c whose disruption increases DHA susceptibility. Screens performed under high
doses of DHA provide evidence that mitochondrial metabolism can modulate resistance. We
show that disrupting a top candidate from the screens, the mitochondrial protease DegP2,
lowers porphyrin levels and decreases DHA susceptibility, without significantly altering
parasite fitness in culture. Deleting the homologous gene in P. falciparum, PfDegP, similarly
lowers heme levels and DHA susceptibility. These results expose the vulnerability of heme
metabolism to genetic perturbations that can lead to increased survival in the presence
of DHA.
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S ince their discovery and characterization as potent anti-malarials, artemisinin (ART), and its synthetic derivativeshave emerged as important drugs in treating infectious
diseases, and are being actively investigated in cancer therapy1,2.
Notably, artemisinin-based combination therapies (ACTs) have
transformed malaria treatment, particularly in response to
widespread resistance to previous classes of antiparasitic com-
pounds. ARTs require activation within cells by scission of an
endoperoxide bridge through the Fe2+ center of heme1,3. Clea-
vage of this bond produces ART radicals that react with a mul-
titude of proteins4,5, lipids6, and metabolites7, rapidly leading to
cell death.
ARTs are labile, and their short half-lives (~1 h in humans)
enable modest, stage-specific reductions in parasite susceptibility
to translate into reduced clinical efficacy. This reduced activity
was first noted in Southeast Asia a decade ago, and is increasingly
frequent8–11. Clinical resistance has been associated with genetic
polymorphisms in Plasmodium falciparum Kelch13 (K13), most
notably K13C580Y 12,13. Two recent publications attributed this
decreased susceptibility to a hemoglobin import defect that pre-
sumably renders parasites less able to activate ART14,15. This
hypothesis may help explain how mutants in other components
of the endocytic machinery, such as coronin16 and clathrin
adaptors17–19, and in hemoglobin digestion20 also confer
decreased susceptibility to ART. Previous studies have also pos-
tulated that the altered ART susceptibility of K13C580Y parasites
involves changes in the unfolded protein response, autophagy,
and PI3K activity, which may contribute to cellular survival fol-
lowing protein alkylation21–24. Some P. falciparum strains with-
out identified causative mutations have also displayed decreased
clearance25,26, suggesting that aspects of ART susceptibility have
yet to be elucidated.
Directed evolution coupled with whole-genome sequencing has
identified targets and resistance pathways for many antiparasitic
compounds16,27–29. Such approaches can be time-consuming,
may fail to detect minor mutations or those that negatively
impact parasite fitness, and can only be used for positive selection
schemes. Recently, whole-genome CRISPR-based mutational
approaches have uncovered drug-resistance mechanisms in can-
cer30–32. Analogously, we have shown that CRISPR screens in
Toxoplasma gondii provide a comparatively fast method to
identify causal mutations using both positive and negative
selection33,34.
Despite species-specific differences that could impact ART
susceptibility—such as the lack of substantial hemoglobin uptake
by T. gondii—here, we demonstrate that a point mutation in K13,
homologous to the canonical P. falciparum K13C580Y, reduced the
susceptibility of T. gondii to dihydroartemisinin (DHA).
Genome-wide screens in T. gondii further identified mutants in a
putative porphyrin transporter (Tmem14c) that are more sus-
ceptible to DHA, as well as mutations in several genes involved in
mitochondrial metabolism that decreased drug susceptibility. In
particular, we identified a mitochondrial protease (DegP2), dis-
ruption of which decreases porphyrins and DHA susceptibility
without impacting parasite fitness. We provide evidence that
DegP2 interacts with several mitochondrial proteins, including
one that contains a NifU domain that is predicted to be involved
in transferring nascent iron–sulfur clusters to client proteins. In
keeping with this observation, ΔDegP2 parasites have alterations
in the electron transport chain (ETC) and the tricarboxylic acid
cycle (TCA)—two iron–sulfur cluster-dependent processes.
Results
Using T. gondii to understand apicomplexan DHA suscept-
ibility. Previous studies have demonstrated the susceptibility of
T. gondii to ART and its derivatives35–37. To establish the sus-
ceptibility of T. gondii to DHA in our assays, we treated intra-
cellular parasites with varying concentrations of DHA or
pyrimethamine (the frontline treatment for toxoplasmosis) for
24 h. Parasite viability was measured by counting the number of
vacuoles containing two or more parasites in vehicle- or drug-
treated conditions. Both drugs completely blocked parasite
replication at 10 µM, which did not affect the integrity of the host
monolayers (Fig. 1a). Our results recapitulate the reported EC50
for pyrimethamine38 and underscore the potency of DHA against
T. gondii. Nevertheless, we recognize that T. gondii is far less
susceptible to DHA than blood-stage malaria parasites, a fact that
contributes to the use of other compounds as frontline drugs for
toxoplasmosis39.
We next determined the length of time required for DHA to
kill extracellular and intracellular parasites. Measuring the
susceptibility of extracellular parasites to DHA allowed us to
exclude possible effects of the compound on host cells. Isolated
parasites were treated with DHA for increasing lengths of time
before removing the compound and allowing parasites to infect
host cells and replicate for 24 h. The effect of DHA (both at 1 μM
and at 10 μM) plateaued after 5 h of treatment (Fig. 1b). We
similarly determined the treatment window for intracellular
parasites. We added 1 or 10 μMDHA to intracellular parasites 1 h
post invasion (1 h.p.i.), washed out the compound after different
lengths of time, then assessed parasite viability based on the
proportion of the host cell monolayer that was lysed 72 h.p.i.
(Fig. 1c). Based on these results, we used 5 h treatments for both
intracellular and extracellular parasites40.
Homologous Kelch13 mutations decrease DHA susceptibility
in P. falciparum and T. gondii. In P. falciparum, point mutations
in Kelch13 (K13), such as C580Y and R539T, correlate with
delayed clearance and increased survival of ring-stage
parasites12,13,41,42. Although K13 is conserved among apicom-
plexans, its role in DHA susceptibility has not been examined in
T. gondii. We chose to make a C627Y mutation in the T. gondii
ortholog of K13 (TGGT1_262150), corresponding to P. falci-
parum C580Y13 (Fig. 1d). Extracellular K13C627Y parasites were
sevenfold less susceptible to DHA compared to the parental strain
(Fig. 1e; EC50 values provided in Supplementary Table 1), indi-
cating that the effect of K13 on DHA susceptibility transcends
genera. As in P. falciparum, K13C627Y parasites were still sus-
ceptible to prolonged DHA exposure and did not form plaques
under continuous DHA treatment (Supplementary Fig. 1).
DHA susceptibility is known to change over the P. falciparum
erythrocytic cycle, with trophozoites displaying greater suscept-
ibility than rings or schizonts43,44. To determine whether active
replication affects DHA susceptibility in T. gondii, we treated
intracellular parasites immediately after invasion (Fig. 1f and
Supplementary Table 1) before most parasites have initiated
replication—or 24 h after invasion when most parasites are
replicating45 (Fig. 1g and Supplementary Table 1). K13C627Y
parasites were at least twofold more resistant to DHA compared
to the parental line, regardless of the timing of treatment
(Fig. 1h), and we conclude that replication does not affect the
reduced DHA susceptibility of K13C627Y T. gondii.
A genome-wide screen identifies a mutant that is hypersensi-
tive to DHA. We performed CRISPR-based screens to identify
genes that when disrupted would increase T. gondii susceptibility
to DHA. Transfecting a library containing ten guide RNAs
(gRNAs) per gene into a large population of parasites that con-
stitutively expressed the Cas9 nuclease, we created a diverse
population of mutants. From previous work, we know that
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parasites acquire on average a single gRNA that directs Cas9 to
create a double-stranded break in the coding sequence of the
specified gene33,34,46. Insertions and deletions introduced during
DNA repair lead to loss-of-function mutations in the targeted
genes, and the prevalence of different mutants in the population
can be inferred from the relative abundance of gRNAs against
each gene. Following generation of the pool of mutants, we
propagated this pool in the presence or absence of a sublethal
dose (50 nM) of DHA for 7 days (three passages for the untreated
population; Fig. 2a). Guides against a single gene
(TGGT1_228110) were substantially depleted under drug treat-
ment compared to the untreated control (Fig. 2b and Supple-
mentary Data 1). TGGT1_228110 encodes a previously unstudied
T. gondii gene with three to four transmembrane domains, pre-
dicted to be dispensable under standard growth conditions34.
Structural prediction using HHPred47 indicated that
TGGT1_228110 is homologous to TMEM14C (p= 5 × 10−21), a
recently identified porphyrin transporter found in mammals48.
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Based on this homology, we named the T. gondii gene Tmem14c.
Tmem14c is conserved in coccidia but absent from Plasmodium
spp., suggesting that this gene plays an accessory role in heme
synthesis.
To validate the effect of Tmem14c depletion on DHA
susceptibility, we replaced the coding region of Tmem14c with
an mNeonGreen expression cassette (Supplementary Fig. 2).
Although ΔTmem14c grew normally under standard conditions,
treating mutant parasites with 100 nM DHA for 7 days abolished
plaque formation, with minimal effects on the parental line
(Fig. 2c). We quantified the change in DHA susceptibility by
treating extracellular parasites with varying concentrations of
DHA, then measuring their viability. Results showed a modest
(twofold) increase in DHA susceptibility for ΔTmem14c parasites
compared to the parental line (Fig. 2d and Supplementary
Table 1).
We considered that treating intracellular parasites would better
resemble the conditions of the CRISPR screens, which maintained
DHA pressure throughout the lytic cycle. We therefore assessed
the DHA susceptibility of ΔTmem14c parasites by treating with
DHA for 5 h immediately after invasion or during replication
(Fig. 2e and Supplementary Table 1). In contrast to the parental
and K13C627Y parasite lines (Fig. 1h), the susceptibility of
ΔTmem14c to DHA was significantly more pronounced during
replication, when it was sevenfold greater than that of the
parental strain.
To examine the function of Tmem14c, we determined its
subcellular localization and the effect of its deletion. A C-
terminally Ty-tagged copy of Tmem14c was found to localize to
the parasite mitochondrion (Fig. 2f), in agreement with the
localization of the mammalian homolog to the inner mitochon-
drial membrane48. We then probed for global metabolic changes
in intracellular ΔTmem14c parasites by targeted metabolomics
(Fig. 2g and Supplementary Data 2). We observed changes in
glycine–serine metabolism, as well as TCA cycle intermediates,
which supports the link between Tmem14c and mitochondrial
function.
Genome-wide screens implicate TCA and heme biosynthesis
pathways in DHA susceptibility. We performed three genome-
wide CRISPR screens, similar to those described above, to identify
genes that when disrupted decrease susceptibility to DHA. Fol-
lowing selection for integration of the gRNAs, parasite popula-
tions were treated with DHA or vehicle, then cultured for the
time required to passage the untreated population three times
(~6 days). The log2-fold change of gRNA abundance between the
drug-treated and untreated populations (drug score) was used to
rank all protein-coding genes (Fig. 3a and Supplementary
Data 1). Two replicates of this screen were performed using 0.5
µM DHA, pooled, and analyzed using Model-based Analysis of
Genome-wide CRISPR/Cas9 Knockout (MaGECK)49. A third
screen performed with 10 µM DHA was analyzed separately. In
total, gRNAs against eight genes were significantly enriched in
DHA-treated populations in at least two of the three high-dose
screens (Supplementary Table 2). A further 65 genes were sig-
nificantly enriched in individual screens (Supplementary Data 3).
The likelihood of identifying a given candidate depends on the
gene’s contribution to overall fitness, as well as the gene’s impact
on DHA susceptibility. For every iteration of the screen, the rate
at which mutants are lost from the population will fluctuate such
that certain fitness-conferring mutants may be completely lost
from the population before they have a chance to impact survival
under DHA treatment. Even candidates identified in a single
screen are significant based on the concordant effect of multiple
gRNAs; however, we have the highest confidence in hits obtained
from multiple independent screens and focused subsequent
analyses on these candidates. Because K13 mutants are exceed-
ingly difficult to recover by selection with DHA in culture12 and
K13 is necessary for T. gondii fitness34, we did not expect
enrichment of gRNAs targeting K13, which would predominantly
cause loss-of-function mutations.
We performed metabolic pathway analysis on the 73 candidate
genes identified by the screens (65 genes identified in single
replicates and 8 genes identified in multiple replicates) and found
that TCA cycle enzymes were significantly enriched (Bonferroni-
adjusted p-value= 1.67 × 10−5). The TCA cycle and heme
biosynthesis are linked through the production of succinyl-
CoA, which is a substrate for δ-aminolevulinic acid synthase
(ALAS; Fig. 3b). Two enzymes from the heme biosynthesis
pathway were among the candidates: porphobilinogen deaminase
(TGGT1_271420) and protoporphyrinogen oxidase
(TGGT1_272490). We also identified pyridoxal kinase, which
functionalizes the cofactor pyridoxal phosphate. This cofactor is
required by several enzymes, including ALAS, which catalyzes the
first step of heme biosynthesis50. Taken together, these screens
support the conclusion that genetically inhibiting heme biosynth-
esis reduces the DHA susceptibility of T. gondii.
Chemical modulation of heme biosynthesis decreases DHA
susceptibility. We investigated whether inhibitors of the TCA
cycle (sodium fluoroacetate, abbreviated as NaFAc)51 or heme
biosynthesis (succinyl acetone, abbreviated as SA)52 would reca-
pitulate our genetic results. After pretreating extracellular para-
sites for 2 h with NaFAc or SA, we treated them for a further 5 h
with increasing concentrations of DHA before determining
parasite viability. Consistent with our genetic results, both NaFAc
and SA significantly increased the EC50 of DHA compared to
untreated parasites (Fig. 3c, d and Supplementary Table 1). To
Fig. 1 DHA kills wild-type T. gondii efficiently and its effect is influenced by mutation of K13. a Treatment with increasing concentrations of
dihydroartemisinin (DHA) or pyrimethamine (Pyr) over 24 h resulted in a reduction in parasite viability, measured as the number of vacuoles with two or
more parasites normalized to untreated wells. Results are mean ± SEM for n= 4 independent experiments. b Viability was similarly assessed for
extracellular parasites treated with 1 or 10 µM DHA for varying periods of time, then washed and allowed to invade host cells. Viable vacuoles were
normalized to untreated parasites kept extracellular for equal periods of time. Results are mean ± SEM for n= 3 independent experiments, each performed
in technical triplicate. c Quantification of host monolayer lysis after treatment with 1 or 10 μM DHA for the indicated time, normalized to uninfected
monolayers. Results are mean ± SEM for n= 4 independent experiments. d Alignment of the mutated region of K13 in P. falciparum and T. gondii displaying
the chromatogram for the K13C627Y T. gondii line. e Extracellular dose–response curve for parental or K13C627Y parasites treated with DHA for 5 h. Results
are mean ± SEM for n= 7 or 5 independent experiments with parental or K13C627Y parasites, respectively. f Monolayer lysis following infection with
parental or K13C627Y parasites for 1 h, prior to a 5 h treatment with varying concentrations of DHA. Results are mean ± SEM for n= 4 independent
experiments. g Monolayer lysis following infection with parental or K13C627Y parasites for 24 h, prior to 5 h treatment with varying concentrations of DHA.
Results are mean ± SEM for n= 4 or 3 independent experiments with parental or K13C627Y parasites, respectively. h Graph summarizing the fold change in
DHA EC50 between parental and K13C627Y parasites, treated 1 or 24 h after invasion. Results are mean ± SD for n= 4 or 3 independent experiments,
p-value calculated from two-tailed unpaired t-test.
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ensure that metabolic modulation alone did not impact DHA
susceptibility, we blocked glycolysis using 5 mM 2-deoxyglucose
(2-DG)51,53, as glycolysis is dispensable for TCA activity in the
presence of glutamine54. Pretreatment with 2-DG did not change
the susceptibility of parasites to DHA (Fig. 3e and Supplementary
Table 1).
To confirm the effect of the inhibitors on heme production, we
quantified total levels of porphyrins—including heme and its
precursor protoporphyrin IX (PPIX)—by measuring porphyrin
fluorescence55. Porphyrin levels were slightly increased by
treatment with 2-DG, whereas treatment with NaFAc or SA
significantly depressed porphyrin levels (Fig. 3f). We also
monitored the effects of 2-DG, NaFAc, and SA by global polar
metabolite profiling. Only subtle changes resulted from SA
treatment. However, we observed the expected changes in TCA
cycle or glycolytic intermediates and neighboring pathways after
NaFAc or 2-DG treatment, respectively (Supplementary Fig. 3
and Supplementary Data 4). These results demonstrate that the
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TCA cycle is required to maintain porphyrin pools in T. gondii,
joining the metabolic pathways identified in our screens and
confirming that modulation of heme levels can result in decreased
DHA susceptibility in apicomplexans.
To test whether increased flux through the heme biosynthesis
pathway could hypersensitize parasites to DHA, we supplemented
the growth medium with ALA, a precursor that stimulates heme
biosynthesis in many organisms56–58. While ALA treatment
increased total porphyrin levels it did not alter DHA suscept-
ibility, leading us to suspect that this increase in porphyrins was
due to a buildup of PPIX, and is not reflective of increased heme
levels (Supplementary Fig. 3).
DegP2 mutants have decreased porphyrin levels and decreased
DHA susceptibility. Having verified the relationship between
heme biosynthesis and DHA susceptibility, we turned our atten-
tion to TGGT1_290840—the most significant hit in our lethal
dose DHA screen lacking a known relationship to heme bio-
synthesis (Fig. 3a). Previously uncharacterized in T. gondii,
TGGT1_290840 shares homology with the DegP family of serine
proteases. A related T. gondii rhoptry protease was recently named
DegP59, so we named TGGT1_290840 DegP2. DegP2 possesses an
identifiable catalytic serine (S569), evident in an alignment with
the Arabidopsis thaliana plastid protease Deg260–62.
We generated a panel of strains to study the localization and
function of DegP2. These included a DegP2 knockout made by
replacing the coding sequence with YFP (ΔDegP2; Fig. 4a). We
complemented this knockout with a C-terminally HA-tagged
allele expressed from the TUB1 promoter (ΔDegP2/DegP2-HA).
We also endogenously tagged DegP2 with a C-terminal Ty
epitope, then mutated DegP2’s catalytic serine, creating two
strains that we refer to as DegP2-Ty and DegP2S569A-Ty,
respectively (Fig. 4b). Both the endogenously Ty-tagged and
ectopically expressed HA-tagged DegP2 were co-localized with
the mitochondrial marker mtHSP70 (Fig. 4b).
Finally, we generated a DegP2 conditional knockdown (cKD)
using the U1 system63. Using a parental strain expressing a
rapamycin-dimerizable Cre recombinase (DiCre), the DegP2
locus is appended with a floxed synthetic 3′ untranslated region
(UTR) followed by multiple U1-binding sites. Adding rapamycin
to this strain activates Cre, and leads to excision of the 3′-UTR
and positioning U1-binding sites directly after the DegP2 coding
sequence, altering the stability of the mRNA (Fig. 4c). We used
immunofluorescence microscopy (Fig. 4c) and immunoblotting
(Fig. 4d) to show that a 2 h pulse of rapamycin leads to robust
DegP2 depletion.
Plaque assays showed that both ΔDegP2 and the complemen-
ted strain ΔDegP2/DegP2-HA had significant growth defects
(Fig. 5a). By contrast, DegP2-Ty and DegP2S569A-Ty lines formed
plaques similarly to the parental strain (Fig. 5b). This led us to
suspect that ΔDegP2 harbors alterations that extend beyond the
activity of the protease. Therefore, we have only attributed to
DegP2 those phenotypes that could be complemented in
ΔDegP2/DegP2-HA or determined using the DegP2 cKD.
As many of the hits from our lethal dose DHA screen were related
to heme biosynthesis—a process that takes place partially in the
mitochondrion, where DegP2 is found—we wondered if disrupting
DegP2 might also decrease parasite heme levels. By measuring
porphyrin fluorescence, we found that ΔDegP2 and DegP2S569A-Ty
both had significantly reduced porphyrin levels, and porphyrin
abundance was partially restored in ΔDegP2/DegP2-HA (Fig. 5c).
To confirm that ΔDegP2’s decreased heme levels correspond to
a decrease in DHA susceptibility, we determined the EC50 of
DHA against the DegP2 knockout and catalytically inactive
strains, along with their respective controls (Fig. 5d and
Supplementary Fig. 4). As expected, we observed a significantly
higher EC50 for ΔDegP2 compared to the parental strain (358 nM
compared to 76 nM). This effect was largely reversed in
ΔDegP2/DegP2-HA (105 nM). Likewise, DegP2S569A-Ty had a
significantly higher EC50 than DegP2-Ty (153 nM compared to
63 nM). When we looked for a correlation between porphyrin
levels and DHA EC50, we found a strong negative relationship
between these strain’s porphyrin levels and DHA susceptibility
(r2= 0.75; Fig. 5e).
We confirmed the relationship between DegP2, porphyrin
levels, and DHA susceptibility using the DegP2 cKD. Rapamycin-
treated DegP2 cKD parasites form plaques similarly to DiCre
parasites (Fig. 5f). Using fluorescence to quantify the porphyrin
levels in the DegP2 cKD revealed a drop of ~30% in response to
rapamycin treatment, similar to the difference observed between
ΔDegP2 and its parental strain (Fig. 5g).
To assess the ability of DegP2 cKD parasites to survive DHA
treatment, we treated the DegP2 cKD strain with rapamycin, or
vehicle, then mixed it in a 1:1 ratio with rapamycin-treated DiCre
parasites expressing tdTomato. Rapamycin treatment of the
DiCre strain had no effect on its fitness and provided an ideal
control for treatment of the cKD. We cultured the resulting
populations in the presence or absence of DHA for 8 days and
used flow cytometry to analyze the composition of the
populations every 2 days (Fig. 5h). Rapamycin-treated DegP2
cKD parasites consistently outcompeted DiCre parasites in the
presence of DHA, whereas levels of both strains remained close to
50% under control conditions. Collectively, these results confirm
that reducing DegP2 levels reduces porphyrin levels, resulting in
decreased susceptibility to DHA.
The decreased porphyrin levels in ΔDegP2 prompted us to
examine metabolic changes in other mutants that modulate DHA
susceptibility. ΔTmem14c and K13C627Y parasites displayed
similar levels of porphyrins as their isogenic controls (Supple-
mentary Fig. 2). Analysis of polar metabolites in the K13C627Y
strain revealed that the metabolic pathway for alanine, aspartate,
Fig. 2 Genome-wide screen under sublethal DHA concentration reveals that loss of Tmem14c increases DHA susceptibility. a Screening workflow. The
drug score is defined as the log2-fold change in the relative gRNA abundance between the DHA-treated and vehicle populations, where lower scores are
indicative of genes that enhance drug susceptibility when disrupted. b Results of a genome-wide CRISPR screen (calculated as described in a) comparing
treatment with 50 nM DHA (equivalent to EC5) to vehicle-treated parasites. Guides against one gene, Tmem14c, were significantly depleted by the
sublethal DHA concentration, but were retained in the vehicle control. c ΔTmem14c parasites formed plaques normally under standard growth conditions,
but their plaquing ability was attenuated in the presence of 100 nM DHA. The parental strain proliferated normally in both conditions. d Extracellular
ΔTmem14c parasites had a decreased EC50 compared to the parental line (p= 0.0003, extra-sum-of-squares F-test). Results are mean ± SEM for n= 7
independent experiments. e Monolayer lysis following infection with parental or ΔTmem14c parasites and treatment with varying concentrations of DHA
during hours 1–6 (top panel) or 24–29 (bottom panel) post infection. Results are mean ± SEM for n= 4 or 3 independent experiments for parental or
ΔTmem14c parasites, respectively. f Overexpression of Tmem14c-Ty co-localized with mitochondrial marker mtHSP70. Scale bar is 5 μm. g Relative
abundance of selected amino acids from targeted metabolomics of intracellular parental or ΔTmem14c parasites. Results are mean ± SD for n= 3 technical
replicates, with p-values calculated by one-way ANOVA.
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and glutamate production changed significantly (FDR < 0.05).
The TCA cycle was also affected (FDR < 0.1), with several
intermediates displaying decreased abundance compared to the
control (Supplementary Fig. 2 and Supplementary Table 3).
Unlike for NaFAc (Supplementary Fig. 3) or ΔDegP2 (discussed
below), this effect does not point to a specific block in the TCA
cycle, but rather a global dysregulation of the pathway. Our
results suggest that in T. gondii, ΔTmem14c and K13C627Y
mutations affect DHA susceptibility independently from the
steady-state heme pools. However, we cannot rule out changes in
subcellular localization of heme, as may be expected from the
predicted role of Tmem14c in porphyrin transport14,15,48.
Total porphyrin concentration
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DegP2 influences the intersection of the TCA cycle, heme
biosynthesis, and the ETC. We attempted to use immunopre-
cipitations with either wild type or catalytically dead DegP2 to
define DegP2’s binding partners, but we were unable to reliably
detect interactions. Instead, we turned to thermal proteome
profiling (TPP) to identify proteins that change in thermal sta-
bility when DegP2 is knocked down64–67, implying a direct or
indirect interaction with DegP2. We collected DegP2 cKD para-
sites that had been treated with rapamycin or a vehicle control,
then heated them to temperatures between 37 °C and 67 °C. After
lysis and ultracentrifugation, only non-denatured proteins
remained in the supernatant. Using liquid chromatography mass
spectrometry (LC–MS), we compared the abundances of non-
denatured proteins across the range of temperatures and identi-
fied proteins that had altered melting temperatures in the absence
of DegP2. We calculated melting temperatures for 1669 proteins
across two replicates of the TPP experiment and identified 13
proteins that displayed greater than average changes in both
replicates (p < 0.2 by z-test; Fig. 6a and Supplementary Data 5).
Of these 13 proteins, three are mitochondrial68,69 a NifU domain-
containing protein (TGGT1_212930), the ATP synthase ɣ sub-
unit (TGGT1_231910), and an unannotated protein
(TGGT1_226500; Fig. 6b).
Two of these three mitochondrial proteins are related to the
ETC. The yeast homolog of TGGT1_212930, Nfu1, transfers
nascent iron–sulfur clusters to complex II, as well as to the TCA
cycle enzyme aconitase70. The ɣ subunit of the ATP synthase is
another critical component of the ETC53. These observations
motivated us to examine the susceptibility of ΔDegP2 parasites to
the complex II inhibitor thenoyltrifluoroacetone (TTFA)71,72, and
the cytochrome b inhibitor atovaquone (ATQ)73,74. Parental and
ΔDegP2/DegP2-HA parasites showed similar responses to TTFA,
while ΔDegP2 parasites were significantly more resistant (Fig. 6c
and Supplementary Table 1). By contrast, the EC50 of ATQ was
unchanged between ΔDegP2 and the parental line (Fig. 6d and
Supplementary Table 1). This specific effect of DegP2 on complex
II is consistent with the known role of Nfu1 in transferring
iron–sulfur clusters to complex II.
To determine whether this apparent alteration in complex II
activity resulted in a mitochondrial polarization defect, we loaded
ΔDegP2 and its parental strain with MitoTracker, then analyzed
their fluorescence using flow cytometry (Supplementary Fig. 4).
Both strains displayed similar fluorescence profiles, indicating
that ΔDegP2 parasites polarize their mitochondrial membrane to
a similar extent as the wild type, despite altered complex II
activity.
The TCA cycle is a common thread connecting heme
biosynthesis and the ETC. Succinate, a TCA intermediate, is a
substrate for both heme biosynthesis and the SDHB subunit of
complex II, which converts it to the subsequent TCA inter-
mediate, fumarate. In addition, yeast Nfu1 binds aconitase, which
uses an iron–sulfur cluster to catalyze the second step in the TCA
cycle70. To gain further insight into the mitochondrial dysregula-
tion of ΔDegP2 parasites, we used polar metabolite profiling via
LC–MS to compare the levels of TCA cycle intermediates in
ΔDegP2 and its parental strain (Fig. 6e and Supplementary
Data 6). We observed reduced levels of succinate, in addition to
altered levels of pyruvate, glutamine, malate, and GABA in
ΔDegP2 parasites. These results show that disrupting DegP2
dysregulates multiple aspects of mitochondrial homeostasis,
centering around the intersection between the ETC, the TCA
cycle, and heme biosynthesis.
P. falciparum DegP (PfDegP) deletion alters heme concentra-
tions and reduces DHA susceptibility during the erythrocytic
cycle. To investigate the role of the P. falciparum DegP2 ortholog,
PfDegP (PF3D7_0807700), in ART susceptibility, we disrupted
the gene in the Cam3.II strain expressing wild-type K13 (Fig. 7a,
b). Cam3.II K13WT is derived from the Cambodian isolate Cam3.
II K13R539T, which shows decreased susceptibility to DHA13. We
compared the susceptibility of Cam3.II ΔPfDegP to Cam3.II
K13WT, and found that Cam3.II ΔPfDegP parasites were less
susceptible to DHA in both the ring and schizont stages than
Cam3.II K13WT parasites. For comparison, the parental strain,
Cam3.II K13R539T, displayed low DHA susceptibility in the ring
stage, as previously described13. Surprisingly, Cam3.II ΔPfDegP
and Cam3.II K13R539T showed similar DHA susceptibility in the
schizont stage (Fig. 7c, d).
To test whether the changes in DHA susceptibility were
correlated with changes in heme concentrations, we fractionated
infected cells and measured free heme, as well as heme associated
with hemoglobin and hemozoin75,76. Trophozoites from either
the Cam3.II ΔPfDegP and Cam3.II K13R539T strains had
significantly lower levels of free heme (Fig. 7e), while heme
associated with hemoglobin or hemozoin remained unchanged
(Fig. 7f, g). The effect of the K13 mutation on trophozoites points
to a link between DHA susceptibility and the availability of free
heme within the parasite. Taken together, these data also
demonstrate that screens in T. gondii can identify resistance
alleles that act through mechanisms conserved across the
Apicomplexan phylum.
Fig. 3 Genome-wide CRISPR screen under high DHA pressure identifies TCA and heme biosynthetic pathways as determinants of DHA susceptibility.
a Aggregated drug scores from two independent genome-wide CRISPR screens performed with a lethal dose of 500 nM DHA. Drug scores defined as the
log2-fold change in the relative gRNA abundance between the DHA-treated and vehicle populations, where higher scores are indicative of genes that
reduce drug susceptibility when disrupted. Genes with consistently high drug scores are highlighted, indicating that their disruption favored parasite
survival under otherwise lethal concentrations of DHA. b Diagram of key metabolic pathways highlighting genes with high drug scores in the screens from
a and a third screen performed with 10 µM DHA, analyzed separately. Predicted localization of enzymes within organelles for the TCA cycle and heme
biosynthesis pathways. 2-DG 2-deoxyglucose, ɑ-KG ɑ-ketoglutarate, ALA δ-aminolevulinic acid, CPIII coproporphyrinogen III, Gly glycine, HMB
hydroxymethylbilane, NaFAc sodium fluoroacetate, PGB porphobilinogen, PPIX protoporphyrin IX, PPGIX protoporphyrinogen IX, SA succinyl acetone. Hits
found in two or more replicates (blue) or only one replicate (yellow) are indicated. c Pretreatment with 500mM NaFAc for 2 h significantly increased the
EC50 of DHA (extra-sum-of-squares F-test, p < 0.0001). Results are mean ± SEM for n= 7 or 4 independent experiments with vehicle or NaFAc treatment,
respectively. d Pretreatment with 10 mM SA significantly increased the EC50 of DHA (extra-sum-of-squares F-test, p < 0.0001). Results are mean ± SEM
for n= 7 or 5 independent experiments with vehicle or SA treatment, respectively. e Pretreatment with 5mM 2-DG did not significantly affect the EC50 of
DHA (extra-sum-of-squares F-test, p= 0.6). Results are mean ± SEM for n= 7 or 3 independent experiments with vehicle or 2-DG treatment, respectively.
f Porphyrin levels (combination of heme and PPIX) in parasites exposed to various compounds, measured by fluorescence and normalized to untreated
parasites (NT). Results are mean ± SD for n= 3 independent experiments, each performed in technical duplicate; p-values from a one-way ANOVA with
Tukey’s test.
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Discussion
Recent studies have shown that modulating hemoglobin import
changes P. falciparum’s susceptibility to ART14,15, and here we
extend these results to show that heme biosynthesis plays a role in
T. gondii’s susceptibility to this drug. Heme has long been thought
to activate ART4,20,57,77, and our results support the conclusion
that heme abundance influences ART susceptibility. These
observations help explain why blood-stage P. falciparum,
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releasing large amounts of heme from the digestion of hemo-
globin, is more susceptible to ART than T. gondii78–80. Interest-
ingly, Babesia spp., which live within erythrocytes but do not take
up hemoglobin, have an intermediate susceptibility to ART81,82,
while Cryptosporidium parvum—which lacks genes necessary for
heme biosynthesis83,84 shows little response to ART85.
T. gondii and P. falciparum differ in their reliance on de novo
heme biosynthesis. Inhibiting heme biosynthesis either chemi-
cally52 or genetically34[,86 reduces the fitness of T. gondii, high-
lighting the importance of de novo heme biosynthesis to this
parasite. Modulation of heme biosynthesis in cancer cells has
similarly been found to alter their susceptibility to ART57. By
contrast, heme biosynthesis pathways are dispensable for P. fal-
ciparum growth during blood stages, although this pathway
appears to be necessary during the mosquito stages87,88. Although
de novo heme synthesis is dispensable for blood-stage P. falci-
parum, the components of this pathway are still expressed, and
studies using radiolabeled substrates for heme biosynthesis have
shown that the process remains active89–91. Our results indicate
that there are important parallels between T. gondii and P. fal-
ciparum responses to DHA, despite T. gondii’s reduced suscept-
ibility to such compounds. Our results also demonstrate the
utility of CRISPR screens in identifying pathways that should be
considered when designing ACTs.
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Mutations in P. falciparum K13, particularly K13C580Y, are
major determinants of ART susceptibility in the field. We now
know that K13 helps mediate hemoglobin uptake, and that the
C580Y mutation reduces DHA susceptibility by reducing protein
abundance and limiting flux through this pathway14,15. We con-
structed an analogous mutation in T. gondii K13, and found that
this mutation also rendered T. gondii less susceptible to DHA. T.
gondii ingests host cytosolic proteins92, and may take up host
heme or precursors at low levels through endocytosis. Some of T.
gondii’s heme biosynthesis enzymes can be disrupted—although at
a large fitness cost to the parasite86,93 further suggesting that
parasites can scavenge intermediates from the host’s heme bio-
synthetic pathway to sustain viability, but are insufficient for
normal growth. It is therefore possible that K13 confers decreased
DHA susceptibility through similar mechanisms in T. gondii and
in P. falciparum. Alternatively, recent results show that K13 can
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relocate to the P. falciparum mitochondrion upon DHA treat-
ment, indicating that in addition to its role in hemoglobin import,
K13 may also influence mitochondrial metabolism94. Such alter-
native functions of K13 are more likely to influence K13’s effect on
DHA susceptibility in T. gondii, given that heme import appears
to play a minor role in this parasite compared to biosynthesis.
CRISPR-based screens can identify sensitizing mutations,
which may help design combinatorial therapies. Screening for
mutants that enhanced susceptibility to a sublethal dose of DHA,
we identified an ortholog of TMEM14C, which has been pro-
posed to import porphyrins across the inner mitochondrial
membrane of mammalian cells48. Although we could not estab-
lish a direct role for Tmem14c as a porphyrin transporter and
cannot formally exclude alternative roles in mitochondrial
metabolism, several lines of evidence lead us to propose that
Tmem14c transports heme out of the mitochondrion in T. gondii.
First, perturbations that decrease heme production decrease DHA
susceptibility instead of increasing it, as occurs from Tmem14c
disruption. Second, ΔTmem14c parasites are most susceptible to
DHA during replication, when increased mitochondrial activity
and higher demands on heme production, and export are likely
taking place51. Third, ΔTmem14c parasites have altered levels of
glycine, a substrate for heme biosynthesis, which could be
explained by negative feedback from excess accumulation of
heme in the mitochondrion. ALAS, the enzyme that utilizes
glycine to perform the first committed step in heme biosynthesis,
has been shown to be regulated by excess heme through a variety
of mechanisms95,96. Finally, the mechanism and substrate speci-
ficity of TMEM14C remain uncharacterized in mammalian cells,
leaving open the possibility that TMEM14C might simply med-
iate passive transport of porphyrins down their concentration
gradient. The predicted role of Tmem14c as a porphyrin trans-
porter leads us to propose that changes in heme availability,
through its accumulation in the mitochondrion, may influence
the susceptibility of parasites to DHA97,98.
Screening for mutants with decreased DHA susceptibility
identified the serine protease DegP2, whose knockout contributed
to the survival of T. gondii and P. falciparum parasites exposed to
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DHA. In both species, the activity of DegP2 or PfDegP could be
linked to decreased porphyrin concentrations, and in P. falci-
parum, we extended these results to show that levels of free heme
were affected by mutating PfDegP. PfDegP complements its
ortholog in Escherichia coli, implying broad functional
conservation99.
Using TPP, we uncovered three mitochondrial proteins that
may interact with DegP2. One of these hits, TGGT1_212930,
contains a NifU domain that in other organisms transfers nascent
iron–sulfur clusters to client proteins100,101. In yeast, these clients
include the TCA cycle enzymes aconitase and SDH2 (SDHB in T.
gondii)—the latter also part of complex II of the ETC70. Bacteria
and yeast use chaperones to transfer iron–sulfur clusters from
NifU domain-containing proteins to their clients102–104, raising
the possibility that DegP2 fulfills a similar role in T. gondii. The
complex II inhibitor TTFA71,72 has an altered EC50 when DegP2
is disrupted, which is consistent with DegP2 interacting with the
complex II component SDHB, through TGGT1_212930. While
this manuscript was in preparation, a study performed using
in vitro evolution found that T. gondii parasites with point
mutations in DegP2 had decreased ART susceptibility105. Inter-
estingly, these researchers also found that such parasites had
altered mitochondrial DNA copy number, which in yeast, has
been linked to changes in aconitase106.
In addition to TGGT1_212930, our TPP results revealed that
DegP2 influenced the stability of two other mitochondrial pro-
teins: the mitochondrial ATP synthase ɣ subunit
(TGGT1_231910), and a protein annotated as hypothetical
(TGGT1_226500). The ɣ subunit is part of the central stalk
around which other components of the ATP synthase complex
rotate, to generate ATP107. In other systems, Deg-family proteins
play roles in the folding, maintenance, and turnover of integral
membrane proteins, such as those involved in the ETC108–110,
and a similar phenomenon may explain the apparent association
between DegP2 and this ATP synthase subunit. TGGT1_226500
has not been studied extensively, although a global analysis of
protein localization predicts it is mitochondrial69 and perhaps
localized to one of the mitochondrial membranes based on the
presence of a predicted transmembrane domain111. Our studies
place DegP2’s function at the intersection of the TCA cycle, the
ETC, and heme biosynthesis. Despite its pleiotropic effects,
parasites can survive without DegP2 under standard growth
conditions, albeit with lower porphyrin concentrations that ren-
der them less susceptible to DHA.
We wondered whether, analogously to the mutation of K13,
disruption of DegP2 would decrease DHA susceptibility in both
T. gondii and P. falciparum. We therefore disrupted the homolog
of DegP2 in P. falciparum, PfDegP. As in T. gondii, these parasites
exhibited decreased porphyrin levels and reduced DHA suscept-
ibility. Our results complement recent studies pointing to a role
for hemoglobin import in modulating DHA susceptibility14,15,
and suggest that mitochondrial heme dynamics can also have a
measurable impact on DHA susceptibility.
Despite critical metabolic differences and over 350 million
years of divergent evolution112, our screens identified multiple
genes involved in heme biosynthesis, as critical determinants of
DHA susceptibility in T. gondii, echoing the results of recent
studies that demonstrate that hemoglobin import greatly affects
P. falciparum’s response to ART14,15. Although the two organ-
isms strike drastically different balances between heme import
and biosynthesis, the availability of free heme emerges as a lim-
iting determinant of the susceptibility of parasites to ARTs. Our
study highlights the power of genome-wide CRISPR screens to
identify conserved mechanisms of drug susceptibility and resis-
tance, and points to their potential use in developing novel
therapeutics.
Methods
T. gondii maintenance and strain construction. T. gondii tachyzoites were grown
in human foreskin fibroblasts (HFFs) maintained at 37 °C with 5% CO2 in D3
(Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, 11965118)
supplemented with 3% heat-inactivated fetal bovine serum and 10 μg/ml genta-
micin (Sigma Aldrich, G1272)). When appropriate, chloramphenicol (Sigma
Aldrich, C3175) was used at 40 μM and pyrimethamine (Sigma Aldrich, 46706)
at 3 μM.
Parasite lines were constructed using CRISPR/Cas9-mediated gene editing as
described previously113 The Cas9-encoding plasmid pU6-Universal is available
from Addgene (#52694). Gibson Assembly114 was used to clone gRNAs into the
BsaI sites in pU6-Universal using homology arms of approximately 20 base pairs.
Epitope tags and point mutations were introduced by transfecting repair oligos,
bearing 40 base pairs of homology with the genome on each end of the mutation or
insertion, along with CRISPR machinery. Such repair oligos were often created by
heating oligonucleotides encoding complementary single-stranded DNA to 99 °C
for 2 min in duplex buffer (100 mM potassium acetate, 30 mM HEPES, pH 7.5),
then allowing DNA to cool slowly to room temperature (RT) over the course of
several hours.
K13C627Y mutant parasites were constructed by transfecting pU6-Universal
encoding the protospacer TTGCTCCTCTCACCACTCCG (oligos P1 and P2 in
Supplementary Data 7) into ΔKU80 parasites along with a repair oligo constructed
by hybridizing the oligos P3 and P4. Converting the TGC that encodes C627 to
TAC eliminated an ItaI site, and restriction digests were used to confirm this
mutation. We also introduced a silent CGG to CGA mutation at R667 to eliminate
the protospacer adjacent motif and prevent re-cleavage by Cas9 after the initial
mutation. Clonal K13C627Y lines were isolated, and the mutation was confirmed by
sequencing the locus using primers P5 and P6.
ΔDegP2 parasites were constructed by co-transfecting ΔKU80 parasites with
two copies of pU6-Universal encoding gRNAs with the sequences GCAGTCCCC
AGCATGGTCGG (P7 and P8 in Supplementary Data 7) and GCGCTCACAAGA
CCTCGCTGG (P9 and P10) to cleave the 5′ and 3′ ends of the ORF, respectively.
These cuts were repaired using a template encoding YFP flanked by 40 nucleotides
of homology to the 5′ and 3′-UTRs of DegP2, constructed by amplifying the
fluorescence marker with P11 and P12. YFP-positive parasites were selected by
FACS, and the insertion was confirmed by PCR and Sanger sequencing, using
primers P13 and P14.
DegP2-Ty parasites were constructed by transfecting pU6-Universal carrying
the gRNA sequence GCGCTCACAAGACCTCGCTGG, together with hybridized
P15 and P16, into the ΔKU80 strain. Clonal lines were isolated using limiting
dilution, and those carrying the Ty tag were identified using immunofluorescence
microscopy115.
ΔDegP2 was complemented by integrating the plasmid pDegP2-HA into an
intergenic region at position 14,87,300 on chromosome VI. pDegP2-HA was
constructed by amplifying DegP2 from cDNA using the primers P17 and P18, and
assembling it with a portion of pDsRed116 that was amplified using the primers P19
and P20. A 200 nucleotide region surrounding the integration locus, with an NheI
site at its center, was cloned into the PstI site of the resulting plasmid. We co-
transfected NheI-linearized pDegP2-HA with a Cas9-expressing plasmid carrying a
gRNA with the sequence GCCGTTCTGTCTCACGATGC46, then selected for
integrants using 40 μM chloramphenicol. Clonal populations carrying DegP2-HA
were confirmed using immunofluorescence microscopy with a mouse anti-HA
antibody.
DegP2S569A-Ty parasites were constructed by transfecting DegP2-Ty parasites
with pU6-Universal encoding a protospacer with the sequence GCCATTAATCCT
GGCAACAG (oligos P21 and P22), and a repair oligo constructed by annealing
P23 and P24. Positive clones were selected based on destruction of a HpyCH4III
restriction site, and confirmed by PCR and Sanger sequencing using primers P23
and P24.
DegP2 cKD parasites were constructed by transfecting DiCre parasites117, with
pU6-Universal carrying the gRNA GCGCTCACAAGACCTCGCTGG (P9 and
P10) along with a repair template encoding an HA tag followed by the T. gondii
CDPK3 3′-UTR flanked by two loxP sites, and followed by four U1 recognition
sites and a DHFR resistance cassette. This repair template was PCR amplified from
a custom-built plasmid using the primers P46 and P47. Following selection with
pyrimethamine, clonal lines were selected based on the presence of the HA tag.
ΔTmem14c parasites were constructed by co-transfecting ΔKU80 parasites with
two copies of pU6-Universal encoding gRNAs with the sequence TCGGATTGC
TATCTGACCAA (oligos P27 and P28) and ACGTCTGATGCCAAGGCGAT
(primers P29 and P30), to cleave the 5′ and 3′ ends of the ORF, respectively. These
cuts were repaired using a PCR product encoding a TUB1 promotor, mNeonGreen
coding sequence, and the SAG1 3′-UTR. This sequence was amplified using the
primers P31 and P32. mNeonGreen-positive parasites were selected by FACS, and
the insertion was confirmed by PCR and Sanger sequencing, using the primers P33
and P34, P35 and P36, and P37 and P38.
Tmem14c-Ty parasites were created by randomly integrating a plasmid
containing Tmem14c-ty into RH parasites. Through PCR and Sanger sequencing
of cDNA, the gene model on ToxoDB was found to be incorrect. The stop codon is
instead found at the start of exon 2, creating a product of 330 bp. This product was
amplified from cDNA using the primers P36 and P39, and assembled into the
pSAG1-GCaMP5 (ref. 118) backbone, in which the chloramphenicol-resistance
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cassette was replaced with DHFR, in frame with a Ty tag between the SAG1
promoter and 3′-UTR. Parasites were selected using pyrimethamine, cloned by
limiting dilution and positive clones selected by immunofluorescence microscopy
for the Ty tag.
DiCre/tdTomato parasites were constructed by integrating a tdTomato
expression cassette into an intergenic region at position 1487300 on chromosome
VI. DiCre parasites119 were co-transfected with a Cas9-expressing plasmid carrying
a gRNA with the sequence GCCGTTCTGTCTCACGATGC46 and a repair
template encoding a TUB1 promotor, tdTomato coding sequence, and the DHFR
3′-UTR, which was amplified from a custom-built plasmid using the primers P44
and P45. tdTomato-positive parasites were selected by FACS, and a clonal
population was isolated using limiting dilution and confirmed by flow cytometry.
Pooled genome-wide screens. Genome-wide CRISPR screens were performed
based on the previously published method33. Briefly, 500 µg of gRNA library lin-
earized with AseI was transfected into ~4 × 108 Cas9-expressing parasites46 divided
between ten individual cuvettes. Parasites were allowed to infect 10 × 15 cm2 plates
of confluent HFFs, and the medium changed 24 h post infection to contain pyr-
imethamine and 10 μg/ml DNaseI. Parasites were passaged upon lysis (between
48–72 h post transfection) and selection continued for three passages. At this point,
parasites with integrated gRNA plasmids were split into two pools and either
treated with indicated concentrations of DHA or left untreated. Untreated parasites
were passaged onto fresh HFFs every 2 days, while the medium on treated parasites
was changed for fresh DHA at the same time point. After a further three passages
of the untreated population, parasites were collected, counted, and gDNA was
extracted, using a DNeasy blood and tissue kit (Qiagen). When parasites were not
limiting (e.g., in the untreated sample) DNA was extracted from 1 × 108 parasites.
When DHA was used for positive selection, DNA was extracted from all recovered
parasites. Integrated gRNA constructs were amplified from 500 ng of extracted
DNA, using the primers P40 and P41 in two independent reactions and pooled.
The resulting libraries were sequenced on a HiSeq 2500 (Illumina) with single-end
reads, using primers P42 and P43.
CRISPR screen data analysis. Sequencing reads were aligned to the gRNA library.
The abundance of each gRNA was calculated and normalized to the total number
of aligned reads. To determine the fitness effect of each guide under DHA across
biological replicates, we made use of the MAGeCK algorithm49. Hits were selected
based on FDR of <0.1 in at least one biological replicate. Metabolic pathways
analysis on hits was performed using ToxoDB120 against KEGG and MetaCyc
pathways, and the Bonferroni-adjusted p-value reported.
Compounds used with T. gondii. DHA (VWR, TCD3793) was prepared at 10 mM
in DMSO as single-use aliquots and used at the indicated concentration. Hemin
(Sigma Aldrich, H9039) was prepared at 10 mM in 0.5 M NaOH. 2-DG (Sigma
Aldrich, D6134) was prepared fresh at 10 mM in D3 and used at a final con-
centration of 5 mM. SA (Sigma Aldrich, D1415) was prepared in PBS as 200 mM
stocks and used at a final concentration of 10 mM. ALA (Sigma Aldrich, A3785)
was prepared fresh in PBS at 200 mM and used at a final concentration of 200 μM.
NaFAc (Fisher Scientific, ICN201080) was prepared at 1M in water and used at a
final concentration 500 µM. ATQ (Sigma Aldrich, A7986) was prepared at 27 mM
in DMSO and used at the indicated concentration. TTFA (Sigma Aldrich, T27006)
was prepared as 10 mM stocks in DMSO and used at the indicated concentrations.
MitoTracker Deep Red FM (Life Technologies, M22426) was used at a final con-
centration of 50 nM. Oligomycin (EMD Millipore, 495455) was used at a final
concentration of 20 μM. Pyrimethamine (Sigma Aldrich, 46706) was prepared in
ethanol at 10 mM. ADP (A2754-100MG) was prepared at 100 mM in water. FCCP
(Sigma Aldrich C2920) was prepared at 50 mM in DMSO.
Lytic assay. A total of 50,000 parasites per well were spun down onto HFFs grown
in 96-well plates. After 1 or 24 h, the medium was removed and replaced with
medium containing vehicle or drug, and parasites were incubated for the indicated
time before the wells were washed, the medium replaced, and the monolayers
incubated until 72 h.p.i. Monolayers were rinsed with PBS, fixed in 95% ethanol or
100% ice-cold methanol for 10 min, and stained with crystal violet (Sigma, C6158)
stain (2% crystal violet, 0.8% ammonium oxalate, and 20% ethanol) for 5 min
before washing excess dye with water and allowing to dry. Absorbance of wells was
read at 570 nm and normalized to drug treated, uninfected wells. Each experiment
was performed with three technical replicates, and results show the mean of at least
four independent experiments.
Pulsed treatment assay. Extracellular parasites were incubated in a total volume
of 100 μl D3 with DHA for the indicated time, spun down, and resuspended in 600
μl of pre-warmed D3 before aliquoting 200 μl of parasites to HFF monolayers on a
clear-bottomed plate and incubating for 24 h. Wells were then fixed in 4% for-
maldehyde for 10 min and stained using rabbit anti-PCNA, and detected using
anti-rabbit Alexa 549. Images were acquired using a Cytation 3 high content
imager, and the number of vacuoles and parasite nuclei per vacuole were quantified
using an automated ImageJ macro. Vacuoles of two or more parasites were con-
sidered to be alive, and the number of such vacuoles in drug-treated wells was
normalized to the number in untreated wells to quantify the lethality of drug
treatment.
Porphyrin assay. Based on published methods55, ~5 × 107 freshly egressed para-
sites were passed through a 3 μm filter, washed once in 10 ml of PBS, then pelleted
and resuspended in 50 μl of H2O, and flash frozen in liquid nitrogen. A total of 20
μl of parasite lysate was then mixed with 200 μl of pre-warmed 1.5 M oxalic acid
(Sigma Aldrich, 75688) and incubated in a thermocycler at 99oC for 30 min. The
total volume was then transferred to a clear-bottomed plate and fluorescence was
detected at 662 nm following excitation at 400 nm. Porphyrin levels were calculated
from a standard curve prepared as above using hemin. Total porphyrin was nor-
malized to protein concentration, as calculated by Bradford assay (BioRad,
5000201). Experiments were performed with two technical replicates, and results
are representative of at least three independent experiments.
Immunofluorescence microscopy. Infected cells were fixed in 4% formaldehyde
for 10 min, then permeabilized with 0.25% Triton X-100 for 8 min. Staining was
performed with mouse anti-Ty115, rabbit anti-mtHSP70 (ref. 121), and mouse anti-
HA (1:1000; Biolegends 901513) and detected with Alexa-Fluor-labeled secondary
antibodies (1:1,000; Thermo Fisher). Nuclei were stained with Hoechst 33258
(Santa Cruz, SC-394039) and coverslips were mounted in Prolong Diamond
(Thermo Fisher, P36961). Images were acquired using an Eclipse Ti epifluorescence
microscope (Nikon) using the NIS elements imaging software. FIJI122 was used for
image analysis and Adobe Photoshop for image processing.
Plaque formation. A total of 500 parasites per well were used to analyze the effect
of drug treatment or gene deletion over the course of 8 days. The monolayers were
then rinsed with PBS, fixed in 95% ethanol or 100% ice-cold methanol for 10 min,
and stained with crystal violet (2% crystal violet, 0.8% ammonium oxalate, and 20%
ethanol) for 5 min.
MitoTracker analysis of ΔDegP2. Parasites were suspended at 1 × 107 parasites
per ml in D3 with or without 30 μM oligomycin. After 15 min at 37 °C, the samples
were mixed 2:1 with MitoTracker (Thermo Fisher Scientific, M7512) in D3,
bringing the final concentration of oligomycin to 20 μM and MitoTracker to 12.5
nM. Parasites were incubated at 37 °C for an additional 30 min, then pelleted, and
resuspended in Ringer’s solution (115 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, 3 mM NaH2PO4, 10 mM HEPES, 10 mM glucose, and 1% FBS), before
analysis by flow cytometry.
Extraction of polar metabolites for LC–MS analysis. Parasites were harvested
from HFFs when approximately half the vacuoles were lysed and prepared as for
transcriptomics. Parasite pellets were quenched in 300 µl ice-cold 75% ACN sup-
plemented with 0.5 µM isotopically labeled amino acids (Cambridge Isotopes,
MSK-A2-1.2), and kept at −20 °C. To extract polar metabolites, samples were
sonicated for ten cycles in a Bioruptor (Diagenode) at 4 °C with 30 s on and 30 s
off, then incubated at 4 °C for 10 min. After a 10 min, 10,000 r.p.m. spin in a
tabletop centrifuge (Eppendorf), the supernatant was collected and the pellet was
washed with 100 µl 75% ACN and spun again. The supernatants from the two spins
were combined. Extracted metabolites were dried in a CentriVap concentrator
equipped with a cold trap (Labconco, Kansas City, MO) and reconstituted in an
appropriate volume of 75% ACN (30–100 µl).
LC–MS targeted analysis for polar metabolites. Polar samples were treated for
small-molecule LC–MS as previously described123. MS data acquisition on a Q
Exactive benchtop orbitrap mass spectrometer equipped with an Ion Max source
and a HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC system
(Thermo Fisher Scientific, San Jose, CA) and was performed in a range of m/z=
70–1000, with the resolution set at 70,000, the AGC target at 1 × 106, and the
maximum injection time (Max IT) at 20 ms. For tSIM scans, the resolution was set
at 70,000, the AGC target was 1 × 105, and the max IT was 250 ms. Relative
quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2
(Thermo Fisher Scientific) and TraceFinder software (Thermo Fisher Scientific,
Waltham, MA), using a 5 p.p.m. mass tolerance and referencing an in-house library
of chemical standards. Pooled samples and fractional dilutions were prepared as
quality controls and only those metabolites were taken for further analysis, for
which the correlation between the dilution factor and the peak area read was >0.95
(high-confidence metabolites). Normalization for relative parasite amounts was
based on the total integrated peak area values of high-confidence metabolites
within an experimental batch after normalizing to the averaged factor from all
mean-centered areas of the isotopically labeled amino acids internal standards. It is
of note that normalizing to protein content by Bradford analysis or the sum of all
area reads from high-confidence metabolites lead to similar results. The data were
further Pareto transformed for MetaboAnalyst-based statistical or pathway
analysis124.
Immunoblotting. Parasites were lysed in 20 mM HEPES, 137 mM NaCl, 10 mM
MgCl2, 1% Triton X-100 supplemented with Halt protease inhibitors (Thermo
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Fisher 78430). Proteins were separated by SDS–PAGE and transferred to nitro-
cellulose membranes. CDPK1 was probed using a custom-made antibody125
(1:20,000) and HA using mouse anti-HA (1:5000; Biolegends 901513).
Competition assays. DiCre/tdTomato and DegP2 cKD parasites were subjected to
a 2-h treatment with 50 nM rapamycin or vehicle control 3 days prior to beginning
competition assays. Rapamycin-treated DiCre/tdTomato parasites were then mixed
with either treated or untreated DegP2 cKD parasites in a 1:1 ratio, and cultured in
the presence of 0.5 μM DHA or vehicle control. The population compositions were
monitored every 2 days using a MACSQuant flow cytometer.
TPP sample preparation. For the purpose of processing biological replicates,
parasites were grown in heavy (Lys8/Arg10) and light SILAC media for three
passages prior to harvest. Between the second and third passage, intracellular
parasites were treated with 50 nM rapamycin or vehicle control for 2 h. Two 15-cm
dishes per treatment were harvested and passed through 0.2 µm filters (EMD
Millipore). The parasites were spun at 1000 × g for 10 min at RT, were washed in 1
ml TPP buffer (142 mM KCl, 1 mM MgCl2, 5.6 mM glucose, and 25 mM HEPES),
and were spun again at 1000 × g for 10 min at RT. The parasite pellet was resus-
pended in 1.2 ml TPP buffer, and 100 µl was aliquoted into PCR-strip tubes.
Parasites were heated at 37, 43, 47, 50, 53, 56, 59, 63, and 67 °C for 3 min using the
gradient function on two 48-well thermal cyclers (BioRad). The tubes were placed
on ice, and the parasites were combined with 20 µl of 6× lysis buffer to a final
concentration of 1% IGEPAL CA-680, 1× Halt protease and phosphatase inhibi-
tors, and 250 U/ml benzonase in TPP buffer. Lysates were spun at 100,000 × g for
20 min in a TLA-100 rotor with a Beckman Ultra MAX ultracentrifuge. The
concentration of soluble protein in the supernatant in the 37 °C samples was
quantified with a DC Protein Assay (BioRad) by comparison to a standard curve of
bovine serum albumin.
Protein digestion and peptide labeling. A volume corresponding to 50 µg of
protein from the 37 °C heavy and light SILAC sample was combined, for 100 µg
total. Equivalent volumes from the remaining temperatures were similarly pooled.
Samples were reduced with 5 mM TCEP for 10 min at 55 °C, and were alkylated
with 15 mM MMTS for 10 min at RT. The samples were desalted and cleared of
detergent using the SP3 protocol126. Proteins were digested at a 1:50 trypsin:protein
ratio in 50 mM HEPES pH 8.5 overnight at 37 °C. Peptides were eluted and
quantified using the Pierce Fluorometric Peptide Assay, and 50 µg of peptides from
the 37 °C sample and the equivalent volume from the remaining temperatures were
labeled with TMT10plex at a 1:2 peptide:tag ratio according to manufacturer’s
instructions (Thermo Fisher Scientific). Labeled peptides from one treatment
condition were pooled and desalted with a SepPak Light (Waters), eluted in 40%
acetonitrile, 0.1% acetic acid, and lyophilized. Peptides were fractionated offline via
reversed-phase high-performance liquid chromatography using Shimadzu LC-
20AD pumps and a 10 cm × 2.1 mm column packed with 2.6 µm Aeris PEPTIDE
XB-C18 media (Phenomenex). The gradient was isocratic 1% A buffer (20 mM
ammonium formate, pH 10 in water) for 1 min at 150 µl/min with increasing B
buffer (100% acetonitrile) concentrations to 16.7% B at 20.5 min, 30% B at 31 min,
and 45% B at 36 min. Fractions were collected with a FRC-10A fraction collector,
and 15 samples were lyophilized for analysis.
LC–MS/MS data acquisition. Each fraction was resuspended in 0.1% formic acid
and analyzed on an Orbitrap Q Exactive HF-X mass spectrometer in positive ion
mode connected to an EASY-nLC chromatography system, using 0.1% formic acid
as solvent A and 80% acetonitrile, 0.1% formic acid as solvent B (Thermo Fisher
Scientific). Peptides were separated at 3 µl/min on a gradient of 6–21% B for 41
min, 21–36% B for 20 min, 36–50% B for 10 min, and 50–100% B over 15 min.
Full-scan spectra were acquired in profile mode with a scan range of 375–1400m/z,
resolution of 120,000, maximum fill time of 50 ms, and AGC target of 3E6 with a
15-s dynamic exclusion window. Precursors were isolated with 0.8m/z window and
fragmented with a NCE of 32. The top 20 MS2 spectra were acquired over a scan
range of 350–1500m/z with a resolution of 45,000, AGC target of 1E5, maximum
fill time of 120 ms, and first fixed mass of 100m/z. Raw data files have been
deposited to the ProteomeXchange Consortium via the PRIDE partner
repository127,128 with the dataset identifier PXD019917.
Protein MS data analysis. Peak lists and protein IDs were generated in Proteome
Discoverer 2.2 using Sequest HT (Thermo Fisher Scientific) and the ToxoDB-45
protein database (ToxoDB.org). The search included the following posttransla-
tional modifications for light samples: dynamic phospho/+79.966 Da (S, T, Y),
dynamic oxidation/+15.995 Da (M), dynamic acetyl/+42.011 Da (N-terminus),
dynamic TMT6plex/+229.163 Da (any N-terminus), dynamic TMT6plex/
+229.163 Da (K), and static methylthio/+45.988 Da (C); and the following post-
translational modifications for heavy samples: dynamic phospho/+79.966 Da (S, T,
Y), dynamic oxidation/+15.995 Da (M), dynamic acetyl/+42.011 Da (N-terminus),
dynamic TMT6plex/+229.163 Da (any N-terminus), dynamic Lys8-TMT6plex/
+237.177 Da (N-terminus), static Lys8-TMT6plex/+237.177 Da (K), static
label:13 C(6)15 N(4)/+10.008 Da (R), and static methylthio/+45.988 Da (C).
Reporter ion intensities and ratios were quantified for unique peptides with a strict
1% FDR, co-isolation threshold of 50%, and S/N of 5. Protein abundance relative to
the sample heated to 37 °C were used as input to the TPP R package66. Input and
output data are provided in Supplementary Data 5.
P. falciparum maintenance and strain construction. P. falciparum asexual blood-
stage parasites were cultured in human erythrocytes (3% hematocrit) and RPMI-
1640 medium supplemented with 2 mM L-glutamine, 50 mg/l hypoxanthine, 25
mM HEPES, 0.225% NaHCO3, 10 mg/l gentamycin, and 0.5% (w/v) Albumax II
(Invitrogen). Parasites were maintained at 37 °C in 5% O2, 5% CO2, and 90% N2.
Cultures were stained with Giemsa, monitored by blood smears fixed in methanol,
and viewed by light microscopy.
Transfections were performed by electroporating ring-stage parasites at 5–10%
parasitemia with 50 μg of purified circular plasmid DNA resuspended in
Cytomix129. One day after electroporation, parasites were exposed to 2.5 nM
WR99210 for 6 days to select for transformed parasites. Parasite cultures were
monitored by microscopy for up to 6 weeks post electroporation, and recrudescent
parasites were screened for editing by PCR. Positively edited bulk cultures were
cloned by limiting dilution in 96-well plates, and flow cytometry was used to screen
for positive parasites after 17–20 days. Parasites were stained with 1× SYBR Green
(ThermoFisher) and 100 nM MitoTracker Deep Red (Invitrogen), and detected
using an Accuri C6 flow cytometer (Becton Dickinson130).
To generate the knockout construct for the serine protease PfDegP
(PF3D7_0807700) a donor sequence (834 bp total) was synthesized (Genewiz) fusing
homology regions located in exon 2 (HR1) and exon 5 (HR2), with the addition of
one nucleotide to introduce a frameshift in exon 5. The donor fragment was cloned
into the pDC2 plasmid131 by amplifying with primers p15 and p16 (Supplementary
Data 7) using the restriction sites EcoRI and AatII. The pDC2 plasmid132 contains a
codon-optimized Cas9 sequence under the regulatory control of the 5′ calmodulin
(PF3D7_1434200) promoter and the 3′ hsp86 (PF3D7_0708500) terminator, as well
as the human DHFR (hDHFR) selectable marker that mediates resistance to the
antiplasmodial agent WR99210 (Jacobus Pharmaceuticals). Two gRNA sequences
(Supplementary Data 7) located in exon 4 were selected using chopchop133 and
cloned into pDC2 using an In-Fusion cloning kit (Takara Bio USA, Inc.). The final
constructs pDC2-coCas9-PfDegPKO-hDHFR were transfected into Cam3.IIWT
parasites as described above. Primers for diagnostic PCRs, as well as sequencing
primers are shown in Fig. 6b and listed in Supplementary Data 7.
Schizont-stage and ring-stage survival assays (SSA38 h and RSA0–3 h). These
assays were carried out as previously described43, with minor modifications. In
brief, parasite cultures were synchronized one to two times using 5% sorbitol
(Fisher). Drug was maintained throughout the assay until assessment of parasite
growth. Synchronized schizonts were incubated in RPMI-1640 containing 15 units/
ml sodium heparin for 15 min at 37 °C to disrupt agglutinated erythrocytes, then
concentrated over a gradient of 75% Percoll (Fisher) and washed once in RPMI-
1640. For the schizont-stage survival assay the concentrated schizonts were counted
and seeded at 0.3% parasitemia followed by a 4 h exposure to 700 nM DHA or 0.1%
DMSO (vehicle control). For the ring-stage survival assay purified schizonts were
incubated for 3 h with fresh red blood cells, to allow time for merozoite invasion.
Cultures were subjected again to sorbitol treatment to eliminate remaining schi-
zonts. A total of 0–3 h post invasion rings were adjusted to 1% parasitemia and 2%
hematocrit, and exposed to 700 nM DHA or 0.1% DMSO (vehicle control) for 4 h.
Cells were washed to remove drug and returned to standard culture conditions for
an additional 66 h. Parasite growth in each well was assessed using flow cytometry.
Between 60,000 and 100,000 events were captured for each well. After 72 h, cultures
generally expanded to 3–5% parasitemia in DMSO-treated controls. Percent sur-
vival of DHA-treated parasites was calculated relative to the corresponding DMSO-
treated control.
Cellular heme fractionation assay. Heme fractionation was performed based on
previously described methods75,76. Briefly, sorbitol-synchronized early ring-stage
parasites (<5 h post invasion) were incubated at 5% parasitemia and 2% hemato-
crit. Trophozoites were harvested at 20 h post incubation. Red blood cells were
lysed with 0.05% saponin followed by multiple washes with PBS to remove traces of
hemoglobin. The pellet was then resuspended in PBS and cell number quantified by
flow cytometry. The remaining parasites were then lysed using hypotonic stress
and sonication. Following centrifugation at 3600 r.p.m. for 20 min at RT, treatment
with 0.2 M HEPES buffer (pH 7.4), 4% SDS (w/v), 0.3 M NaCl, 25% pyridine, 0.3 M
NaOH, 0.3 M HCl, and distilled water, the fractions corresponding to hemoglobin,
free heme, and hemozoin were recovered as solution. The UV–visible spectrum of
each heme fraction as an Fe(III)heme–pyridine complex was measured using a
multi-well plate reader (Spectramax 340PC; Molecular Devices). The total amount
of each heme species was quantified using a standard curve prepared from a
standard solution of porcine hematin (Sigma Aldrich) serially diluted in the same
solvents used to process the pellets. The mass of each heme species in femtogram
per cell (fg/cell) was then calculated by dividing the total amount of each heme
species by the corresponding number of parasites. Statistical comparisons were
made using one-way ANOVA (GraphPad Software Inc., La Jolla, CA, USA).
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Statistics and reproducibility. All biological replicates were performed with
independently derived parasite populations. Continuous variable data were pre-
sented as the mean ± SD unless indicated. Where indicated, statistical tests were
performed on raw data, prior to normalization. The significance of differences was
assessed by unpaired, two-tailed Student’s t-test. A one- or two-way ANOVA
followed by Sidak’s or Dunnett’s multiple comparison tests were used where
appropriate when the mean values of more than three groups were compared. P-
values of <0.05 were defined as significant. All statistical analyses were performed
and visualized by GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA, USA).
Tables and results were visualized in Excel (Microsoft). All representative experi-
ments were performed at least twice with comparable results.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
CRISPR screening raw data are available through the Gene Expression Omnibus with the
accession number GSE153785. Minimally processed CRISPR screen data are available in
Supplementary Data 1. Raw thermal proteome profiling data are available through the
ProteomeXchange Consortium via the PRIDE partner repository127 with the dataset
identifier PXD019917. Minimally processed thermal proteome profiling data is available
in Supplementary Data 5. Additional data is available from the authors upon request. T.
gondii genome information can be found in ToxoDB. Source data are provided with
this paper.
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